STOCK TITAN
  1. Home
  2. News
  3. TGTX

TG Therapeutics Inc - TGTX STOCK NEWS

Welcome to our dedicated news page for TG Therapeutics (Ticker: TGTX), a resource for investors and traders seeking the latest updates and insights on TG Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect TG Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of TG Therapeutics's position in the market.

News
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
Rhea-AI Summary
TG Therapeutics, Inc. announces data presentations from Phase 3 trials for BRIUMVI® in patients with relapsing forms of multiple sclerosis at ACTRIMS annual forum.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.34%
Tags
none
-
News
Precision BioSciences Receives Initial $7.5 Million Cash Payment and Equity Investment from TG Therapeutics for Azel-Cel in Treatment of Autoimmune Diseases
Rhea-AI Summary
Precision BioSciences (DTIL) receives upfront cash payment and equity investment from TG Therapeutics (TGTX) for an exclusive license to develop Azercabtagene Zapreleucel for autoimmune diseases, with potential payments totaling $17.5 million. Precision also expects to receive up to $288 million in milestone payments and royalties on net sales, extending its cash runway into the first half of 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2830.47%
Tags
none
-
News
TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anticipated Milestones
Rhea-AI Summary
TG Therapeutics, Inc. (NASDAQ: TGTX) announced preliminary U.S. net product revenue for BRIUMVI® for the fourth quarter and full year ended December 31, 2023. The company reported approximately $40 million in net product revenue for the fourth quarter and $89 million for the full year. The year-end 2023 cash position was approximately $215 million. TG Therapeutics also provided financial guidance and development milestones for 2024, including targets for net product revenue and operating expenses, as well as plans to expand the utility of BRIUMVI and the R&D program with the licensing of azer-cel, an allogeneic CD19 CAR T therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.42%
Tags
none
News
TG Therapeutics Announces Global License Agreement with Precision BioSciences for the Development and Commercialization of Precision’s Allogeneic CD19 CAR T Cell Therapy Program for the Treatment of Autoimmune Diseases
Rhea-AI Summary
TG Therapeutics, Inc. (TGTX) announces partnership with Precision BioSciences, Inc. (DTIL) to acquire a worldwide license to Precision’s Azercabtagene Zapreleucel (azer-cel) for autoimmune diseases and non-oncology indications. The company plans to evaluate the program in multiple autoimmune indications with an investigational new drug (IND) filing targeted for mid-2024. TG Therapeutics will receive exclusive worldwide rights to develop and commercialize azer-cel in non-oncology indications in exchange for upfront and potential near-term economics valued at $17.5 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.36%
Tags
none
-
News
Precision BioSciences Completes License Deal with TG Therapeutics for Cell Therapy Azer-Cel in Treatment of Autoimmune Diseases
Rhea-AI Summary
Precision BioSciences, Inc. (Nasdaq: DTIL) has completed a strategic transaction with TG Therapeutics, Inc. to develop Azercabtagene Zapreleucel (azer-cel) for autoimmune diseases. Precision will receive $17.5 million upfront and near-term payments, with potential for up to $288 million in other development milestone payments. The upfront cash and near-term payments are expected to extend Precision’s cash runway into the first half of 2026 and fund Precision’s Wholly-Owned In Vivo Gene Editing Programs through PBGENE-HBV and PBGENE-PMM Phase I Clinical Data.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.1%
Tags
none
-
News
TG Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
TG Therapeutics, Inc. (NASDAQ: TGTX) announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 4:30 PM PT. A live webcast of the presentation will be available on the Events page of the Company’s website, with a replay available following the event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.05%
Tags
conferences
News
TG Therapeutics to Participate in the 6th Annual Evercore ISI HealthCONx Conference
Rhea-AI Summary
TG Therapeutics, Inc. (TGTX) announces CEO's participation in the 6th Annual Evercore ISI HealthCONx Conference on November 29, 2023. The fireside chat will be available via live webcast on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.86%
Tags
conferences
-
News
TG Therapeutics to Participate in the 5th Annual Guggenheim Inflammation, Neurology & Immunology (INI) Conference
Rhea-AI Summary
TG Therapeutics, Inc. (NASDAQ: TGTX) announced that its Chairman and CEO, Michael S. Weiss, will participate in the 5th Annual Guggenheim Inflammation, Neurology & Immunology (INI) Conference on November 6-7, 2023. The fireside chat with Weiss is scheduled for November 6 at 3:10 PM ET and will be webcasted live on the Company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.24%
Tags
conferences
-
News
TG Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results
Rhea-AI Summary
TG Therapeutics, Inc. reported total net revenue of $165.8 million in Q3 2023, including $25.1 million in BRIUMVI net sales in the United States and $140.0 million in license revenue from Neuraxpharm. The company has achieved over 2,200 BRIUMVI prescriptions since launch, with payor coverage in place for approximately 95% of covered lives. TG Therapeutics also presented positive data from clinical trials and has a cash position of $229.2 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
30.92%
Tags
earnings
News
TG Therapeutics to Host Conference Call on Third Quarter 2023 Financial Results and Business Update
Rhea-AI Summary
TG Therapeutics, Inc. (NASDAQ: TGTX) will hold a conference call on November 1, 2023, at 8:30 AM ET to discuss third quarter 2023 results and provide a business outlook. Michael S. Weiss, Chairman and CEO, will host the call. Participants can join by calling 1-877-407-8029 (U.S.) or 1-201-689-8029 (outside the U.S.) with the conference title 'TG Therapeutics'. A live webcast will be available on the company's website, and an audio recording will be accessible for 30 days after the call.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.18%
Tags
conferences earnings
Stock TGTX logo
TG Therapeutics Inc

Nasdaq:TGTX

TGTX Rankings

#1813 Ranked by Market Cap
#924 Ranked by Stock Gains
N/A Ranked by Dividends

TGTX Stock Data

2.19B
134.88M
9.08%
59.26%
22.25%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
New York

About TGTX

tg therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for b-cell malignancies and autoimmune diseases. currently, the company is developing two therapies targeting hematological malignancies. tg-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the cd20 antigen found on mature b-lymphocytes. tg therapeutics is also developing tgr-1202, an orally available pi3k delta inhibitor. the delta isoform of pi3k is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of b-lymphocytes. both tg-1101 and tgr-1202 are in clinical development for patients with hematologic malignancies. the company also has pre-clinical programs to develop irak4 inhibitors, and anti-pd-l1 and anti-gitr antibodies. tg therapeutics is headquartered in new york city and is traded on nasdaq under the ticker symbol "tgtx".